Lv32
320 积分 2023-10-29 加入
Hyperprogressive disease: recognizing a novel pattern to improve patient management
24分钟前
待确认
Experimental design considerations and statistical analyses in preclinical tumor growth inhibition studies
8天前
已完结
CD25-targeted antibody–drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma
11天前
已完结
Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents
11天前
已完结
Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine
14天前
已完结
Data from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
15天前
已关闭
Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile
28天前
已完结
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine
1个月前
已完结
T Cell Exhaustion and Activation Markers in Pancreatic Cancer: A Systematic Review
1个月前
已完结
The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer
1个月前
已完结
皖公网安备34019202002308
